Oral symptoms and oral mucosal lesions in patients with inflammatory bowel disease treated with anti- TNF-alpha (CROSBI ID 712996)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Muhvić Urek, Miranda ; Saltović, Ema ; Mijandrušić Sinčić, Brankica
engleski
Oral symptoms and oral mucosal lesions in patients with inflammatory bowel disease treated with anti- TNF-alpha
Introduction: Biological therapy has been used for the past 20 years in the treatment of inflammatory bowel disease (IBD). Although this therapy has significantly resulted in the improvement of symptoms and the achievement of disease remission, the use of these drugs is accompanied by side effects in many organs and systems of the body including the oral cavity. The aim of this study was to determine oral symptoms and oral mucosal lesions in patients with IBD treated with anti- tumor necrosis factor-alpha (anti-TNF-alpha). Materials and methods: The study included 20 IBD patients treated with anti-TNF-alpha (infliximab i.v.) (mean age 45.5±18.2, 13 men), 20 IBD patients who did not receive biological therapy (mean age 47.1±10.8, 5 men), and 20 healthy control subjects (mean age 47.2±11, 11 men). Subjects completed a questionnaire about oral symptoms. The presence of oral mucosal lesions were recorded through clinical examination. Results: IBD patients most often complain of bad breath, 30% in the group treated with anti-TNF- alpha, 45% in the group of patients who did not receive biological therapy. Other symptoms (dry mouth, burning sensations, taste disturbance) were reported in small percentages. Specific oral lesions were not recorded in this study. The most lesions were recorded on tongue (coated tongue and atrophic tongue), but no statistically significant difference was found between the groups (p>0.05). Conclusion: According to our results, patients treated with anti-TNF-alpha do not report more oral symptoms and do not have significantly more oral lesions compared to IBD patients without biological therapy and control subjects.
Therapy, biological ; Inflammatory bowel disease ; Oral mucosa
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
52-52.
2021.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Abstract book
Podaci o skupu
15th Biennial congress European association of oral medicine
poster
23.09.2021-25.09.2021
Porto, Portugal